Viridian Cash And Short Term Investments vs Other Current Assets Analysis

VRDN Stock

USD 21.03 0.83 4.11%

Viridian Therapeutics financial indicator trend analysis is much more than just breaking down Viridian Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viridian Therapeutics is a good investment. Please check the relationship between Viridian Therapeutics Cash And Short Term Investments and its Other Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.

Cash And Short Term Investments vs Other Current Assets

Cash And Short Term Investments vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Viridian Therapeutics Cash And Short Term Investments account and Other Current Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Viridian Therapeutics' Cash And Short Term Investments and Other Current Assets is 0.96. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Viridian Therapeutics, assuming nothing else is changed. The correlation between historical values of Viridian Therapeutics' Cash And Short Term Investments and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Viridian Therapeutics are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Cash And Short Term Investments i.e., Viridian Therapeutics' Cash And Short Term Investments and Other Current Assets go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Viridian Therapeutics balance sheet. This account contains Viridian Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Viridian Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from Viridian Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viridian Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.At this time, Viridian Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Sales General And Administrative To Revenue is likely to grow to 317.67, while Issuance Of Capital Stock is likely to drop about 23.8 M.

	2021	2022	2023	2024 (projected)
Interest Expense	3K	486K	1.8M	1.9M
Depreciation And Amortization	620K	755K	522K	437.8K

Interest Expense Depreciation And Amortization

Viridian Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock Total Equity	Common Stock
Total Assets		0.25	0.99	0.66	1.0	0.94	-0.4	-0.87	-0.98	0.61	0.93	0.69	0.57	1.0	-0.61	0.98	0.83	-0.59	0.96	0.99	0.85	0.93	1.0	-0.38	0.83	0.86
Short Long Term Debt Total	0.25		0.23	0.7	0.2	0.32	-0.12	0.11	-0.24	-0.11	0.11	-0.09	-0.17	0.25	0.15	0.34	0.46	0.06	0.3	0.26	0.71	0.17	0.25	0.7	0.21	0.28
Other Current Liab	0.99	0.23		0.63	0.99	0.93	-0.46	-0.84	-0.98	0.54	0.89	0.65	0.52	0.99	-0.55	0.97	0.8	-0.57	0.93	0.97	0.82	0.91	0.99	-0.38	0.76	0.8
Total Current Liabilities	0.66	0.7	0.63		0.63	0.71	-0.45	-0.45	-0.61	0.53	0.6	0.59	0.51	0.66	-0.2	0.67	0.45	-0.2	0.57	0.63	0.9	0.68	0.66	0.42	0.44	0.47
Total Stockholder Equity	1.0	0.2	0.99	0.63		0.94	-0.4	-0.88	-0.98	0.61	0.93	0.7	0.58	1.0	-0.63	0.98	0.82	-0.6	0.95	0.99	0.82	0.93	1.0	-0.42	0.83	0.85
Property Plant And Equipment Net	0.94	0.32	0.93	0.71	0.94		-0.57	-0.73	-0.89	0.56	0.81	0.68	0.54	0.94	-0.48	0.96	0.74	-0.35	0.85	0.93	0.84	0.96	0.94	-0.23	0.71	0.75
Current Deferred Revenue	-0.4	-0.12	-0.46	-0.45	-0.4	-0.57		0.21	0.34	-0.23	-0.24	-0.42	-0.36	-0.4	-0.08	-0.39	-0.05	-0.23	-0.17	-0.33	-0.33	-0.51	-0.39	-0.12	0.14	0.04
Net Debt	-0.87	0.11	-0.84	-0.45	-0.88	-0.73	0.21		0.82	-0.84	-0.98	-0.84	-0.8	-0.87	0.62	-0.79	-0.6	0.71	-0.83	-0.84	-0.6	-0.8	-0.86	0.57	-0.78	-0.77
Retained Earnings	-0.98	-0.24	-0.98	-0.61	-0.98	-0.89	0.34	0.82		-0.5	-0.88	-0.59	-0.45	-0.98	0.65	-0.96	-0.84	0.67	-0.96	-0.99	-0.82	-0.88	-0.98	0.4	-0.84	-0.87
Accounts Payable	0.61	-0.11	0.54	0.53	0.61	0.56	-0.23	-0.84	-0.5		0.8	0.97	0.98	0.61	-0.4	0.53	0.22	-0.42	0.51	0.55	0.47	0.67	0.6	-0.26	0.51	0.48
Cash	0.93	0.11	0.89	0.6	0.93	0.81	-0.24	-0.98	-0.88	0.8		0.81	0.75	0.93	-0.59	0.87	0.72	-0.7	0.9	0.9	0.76	0.84	0.93	-0.43	0.83	0.83
Non Current Assets Total	0.69	-0.09	0.65	0.59	0.7	0.68	-0.42	-0.84	-0.59	0.97	0.81		0.97	0.69	-0.41	0.62	0.26	-0.36	0.55	0.63	0.53	0.79	0.69	-0.26	0.49	0.47
Non Currrent Assets Other	0.57	-0.17	0.52	0.51	0.58	0.54	-0.36	-0.8	-0.45	0.98	0.75	0.97		0.57	-0.33	0.48	0.13	-0.34	0.43	0.5	0.41	0.66	0.56	-0.24	0.39	0.36
Cash And Short Term Investments	1.0	0.25	0.99	0.66	1.0	0.94	-0.4	-0.87	-0.98	0.61	0.93	0.69	0.57		-0.61	0.98	0.82	-0.59	0.96	0.99	0.85	0.93	1.0	-0.38	0.83	0.86
Net Receivables	-0.61	0.15	-0.55	-0.2	-0.63	-0.48	-0.08	0.62	0.65	-0.4	-0.59	-0.41	-0.33	-0.61		-0.58	-0.47	0.59	-0.63	-0.66	-0.36	-0.52	-0.61	0.57	-0.74	-0.7
Common Stock Shares Outstanding	0.98	0.34	0.97	0.67	0.98	0.96	-0.39	-0.79	-0.96	0.53	0.87	0.62	0.48	0.98	-0.58		0.86	-0.49	0.96	0.99	0.87	0.91	0.98	-0.32	0.83	0.86
Non Current Liabilities Total	0.83	0.46	0.8	0.45	0.82	0.74	-0.05	-0.6	-0.84	0.22	0.72	0.26	0.13	0.82	-0.47	0.86		-0.57	0.93	0.86	0.79	0.64	0.83	-0.31	0.86	0.89
Inventory	-0.59	0.06	-0.57	-0.2	-0.6	-0.35	-0.23	0.71	0.67	-0.42	-0.7	-0.36	-0.34	-0.59	0.59	-0.49	-0.57		-0.68	-0.61	-0.41	-0.42	-0.59	0.49	-0.75	-0.74
Other Current Assets	0.96	0.3	0.93	0.57	0.95	0.85	-0.17	-0.83	-0.96	0.51	0.9	0.55	0.43	0.96	-0.63	0.96	0.93	-0.68		0.97	0.83	0.81	0.96	-0.41	0.92	0.95
Other Stockholder Equity	0.99	0.26	0.97	0.63	0.99	0.93	-0.33	-0.84	-0.99	0.55	0.9	0.63	0.5	0.99	-0.66	0.99	0.86	-0.61	0.97		0.84	0.91	0.99	-0.4	0.87	0.9
Total Liab	0.85	0.71	0.82	0.9	0.82	0.84	-0.33	-0.6	-0.82	0.47	0.76	0.53	0.41	0.85	-0.36	0.87	0.79	-0.41	0.83	0.84		0.77	0.85	0.14	0.71	0.75
Property Plant And Equipment Gross	0.93	0.17	0.91	0.68	0.93	0.96	-0.51	-0.8	-0.88	0.67	0.84	0.79	0.66	0.93	-0.52	0.91	0.64	-0.42	0.81	0.91	0.77		0.93	-0.3	0.71	0.73
Total Current Assets	1.0	0.25	0.99	0.66	1.0	0.94	-0.39	-0.86	-0.98	0.6	0.93	0.69	0.56	1.0	-0.61	0.98	0.83	-0.59	0.96	0.99	0.85	0.93		-0.38	0.83	0.86
Short Term Debt	-0.38	0.7	-0.38	0.42	-0.42	-0.23	-0.12	0.57	0.4	-0.26	-0.43	-0.26	-0.24	-0.38	0.57	-0.32	-0.31	0.49	-0.41	-0.4	0.14	-0.3	-0.38		-0.46	-0.42
Common Stock Total Equity	0.83	0.21	0.76	0.44	0.83	0.71	0.14	-0.78	-0.84	0.51	0.83	0.49	0.39	0.83	-0.74	0.83	0.86	-0.75	0.92	0.87	0.71	0.71	0.83	-0.46		0.99
Common Stock	0.86	0.28	0.8	0.47	0.85	0.75	0.04	-0.77	-0.87	0.48	0.83	0.47	0.36	0.86	-0.7	0.86	0.89	-0.74	0.95	0.9	0.75	0.73	0.86	-0.42	0.99

Click cells to compare fundamentals

Viridian Therapeutics Account Relationship Matchups

Viridian Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.3M	131.3M	203.7M	435.1M	490.4M	514.9M
Short Long Term Debt Total	8.3M	455K	520K	5.3M	21.0M	22.1M
Other Current Liab	100K	9.2M	10.5M	18.2M	23.3M	24.4M
Total Current Liabilities	10.2M	10.7M	13.6M	33.3M	26.6M	28.0M
Total Stockholder Equity	15.8M	120.0M	187.7M	395.1M	442.0M	464.1M
Property Plant And Equipment Net	523K	787K	2.1M	2.9M	3.3M	3.5M
Current Deferred Revenue	5.0M	301K	289K	288K	259.2K	246.2K
Net Debt	(16.5M)	(45.4M)	(41.8M)	(150.3M)	(81.8M)	(77.7M)
Retained Earnings	(168.2M)	(278.9M)	(358.3M)	(488.2M)	(725.9M)	(689.6M)
Accounts Payable	1.1M	670K	2.3M	14.2M	2.2M	2.1M
Cash	24.8M	45.9M	42.3M	155.6M	102.8M	108.0M
Non Current Assets Total	523K	1.6M	3.5M	10.5M	3.9M	2.6M
Non Currrent Assets Other	(523K)	857K	1.5M	7.6M	604K	1.0M
Cash And Short Term Investments	26.8M	127.6M	197.0M	424.6M	477.4M	501.2M
Net Receivables	24K	108K	451K	102K	91.8K	87.2K
Common Stock Shares Outstanding	2.1M	3.6M	11.9M	32.1M	44.8M	47.0M
Liabilities And Stockholders Equity	30.3M	131.3M	203.7M	435.1M	490.4M	514.9M
Non Current Liabilities Total	4.3M	544K	2.4M	6.7M	21.8M	22.9M
Other Current Assets	2.8M	2.0M	2.6M	6.5M	9.0M	9.5M
Other Stockholder Equity	183.6M	218.1M	412.1M	741.1M	960.5M	1.0B
Total Liab	14.5M	11.2M	16.0M	40.0M	48.4M	50.8M
Property Plant And Equipment Gross	523K	787K	3.8M	4.9M	4.4M	4.6M
Total Current Assets	29.7M	129.6M	200.2M	424.6M	486.5M	510.8M
Accumulated Other Comprehensive Income	(3.3M)	(8K)	(157K)	(390K)	338K	354.9K
Short Term Debt	4.0M	455K	520K	613K	843K	800.9K
Common Stock Total Equity	349K	42K	239K	414K	476.1K	499.9K
Common Stock	349K	42K	239K	414K	540K	567K
Net Tangible Assets	15.8M	(60.8M)	53.9M	252.9M	290.9M	305.4M
Property Plant Equipment	523K	787K	375K	1.3M	1.5M	774.1K
Net Invested Capital	24.1M	(60.8M)	53.9M	257.6M	255.7M	268.5M
Net Working Capital	19.6M	118.9M	186.5M	397.8M	459.8M	482.8M
Short Term Investments	2.0M	81.7M	154.7M	269.0M	374.5M	393.3M
Capital Stock	349K	180.8M	134.1M	142.6M	207.1M	122.0M

Pair Trading with Viridian Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Viridian Stock

0.76	BACK	IMAC Holdings	Pair Corr
0.67	VALN	Valneva SE ADR	Pair Corr
0.51	NKTX	Nkarta Inc	Pair Corr
0.47	MTEM	Molecular Templates	Pair Corr
0.47	CYRX	Cryoport	Pair Corr

The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.

The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:

How To Invest In Viridian

Details

Is Viridian Stock a good investment?

Details

What is Viridian Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.32)

Revenue Per Share

0.005

Quarterly Revenue Growth

0.194

Return On Assets

(0.32)

Return On Equity

(0.52)

The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viridian Cash And Short Term Investments vs Other Current Assets Analysis

Cash And Short Term Investments vs Other Current Assets

Cash And Short Term Investments vs Other Current Assets Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Other Current Assets

Viridian Therapeutics fundamental ratios Correlations

Viridian Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viridian Therapeutics fundamental ratios Accounts

Pair Trading with Viridian Therapeutics

Moving against Viridian Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.98	Other Current Liab